SCHEMBL6646364

SCHEMBL6646364

COC(=O)c1cc(F)c(F)c(OCF)c1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.39
▸ MAPT P10636 4/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ HTT P42858 1/20 0.39
▸ TDP1 Q9NUW8 2/20 0.35
▸ SOS1 Q07889 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ CA12 O43570 2/20 0.34
▸ CA1 P00915 2/20 0.34
▸ CA2 P00918 2/20 0.34
▸ CA7 P43166 2/20 0.34
▸ CA9 Q16790 2/20 0.34
▸ CA14 Q9ULX7 2/20 0.34
▸ GAA P10253 2/20 0.34
▸ POLB P06746 2/20 0.34
▸ PDK2 Q15119 1/20 0.34
▸ PDK4 Q16654 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6642984 0.84 TSHR (0.44) KDM4EMAPTALDH1A1HTTMAPK1
SCHEMBL2831221 0.83 KDM4E (0.45) KDM4EALDH1A1TDP1SOS1CA12
SCHEMBL6644694 0.80 MAPT (0.38) KDM4EMAPTALDH1A1HTTMAPK1
SCHEMBL6645891 0.79 KDM4E (0.39) KDM4EMAPTALDH1A1HTTTDP1
SCHEMBL1994444 0.79 MAPT (0.43) KDM4EMAPTALDH1A1TDP1SOS1
SCHEMBL31579013 0.78 FFAR4 (0.46) KDM4EMAPTALDH1A1HTTGAA
SCHEMBL7441202 0.76 HSD17B10 (0.35) KDM4EMAPTALDH1A1SOS1CA12
SCHEMBL6647182 0.74 MAPT (0.40) KDM4EMAPTALDH1A1TDP1SOS1
SCHEMBL6644948 0.74 KDM4E (0.47) KDM4EMAPTALDH1A1TDP1CA12
SCHEMBL6647223 0.74 MAPT (0.33) KDM4EMAPTALDH1A1HTTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401830-A2 QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS Warner-Lambert Company LLC (US) 2004-03-31 — — EP disclosed
US-20030114666-A1 Having quinazolindione core structure; non-antibiotic resistance WARNER-LAMBERT COMPANY 2003-06-19 — — US disclosed
WO-2002102793-A2 QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY LLC (US) 2002-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114666-A1 Having quinazolindione core structure; non-antibiotic resistance ABCC1, RPS6KA1, SIGMAR1 KDM4E 1886/4885MAPT 4486/4885ALDH1A1 781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback